Compare
GeneDx Holdings Corp. vs Omada Health, Inc. vs Pennant Group, Inc. vs InnovAge Holding Corp.
| Latest fiscal year | GeneDx Holdings Corp. WGS | Omada Health, Inc. OMDA | Pennant Group, Inc. PNTG | InnovAge Holding Corp. INNV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $427.54M | $260.21M | $947.71M | $989.71M |
| Revenue growth (YoY) | +40.0% | +53.2% | +36.3% | +15.9% |
| Gross margin | 69.7% | 65.7% | n/a | 23.0% |
| Operating margin | -3.1% | -4.6% | 5.5% | 0.3% |
| Net margin | -4.9% | -4.9% | 3.1% | -0.3% |
| Net income | -$21.02M | -$12.78M | $29.58M | -$2.54M |
| EPS (Diluted) | -$0.73 | -$0.35 | $0.84 | -$0.02 |
| Operating cash flow | $33.28M | $18.25M | $48.29M | $64.71M |
| Free cash flow | $14.26M | $16.93M | $36.26M | $50.41M |
| Cash & equivalents | $105.00M | $222.04M | n/a | $97.89M |
| Total assets | $523.71M | $305.41M | $968.18M | $557.39M |
| Total liabilities | $215.53M | $75.73M | $593.93M | $288.62M |
| Shareholders' equity | $308.18M | $229.68M | $374.25M | $235.60M |
| Return on year-end equity | -6.8% | -5.6% | 7.9% | -1.1% |
| Shares outstanding | 29.25M | 58.43M | 34.63M | 136.02M |
Revenue, most recent five fiscal years
| Fiscal year | GeneDx Holdings Corp. | Omada Health, Inc. | Pennant Group, Inc. | InnovAge Holding Corp. |
|---|---|---|---|---|
| Latest | $427.54M Ended 2025-12-31 | $260.21M Ended 2025-12-31 | $947.71M Ended 2025-12-31 | $989.71M Ended 2026-06-30 |
| 1 year earlier | $305.45M Ended 2024-12-31 | $169.80M Ended 2024-12-31 | $695.24M Ended 2024-12-31 | $853.70M Ended 2025-06-30 |
| 2 years earlier | $202.57M Ended 2023-12-31 | $122.78M Ended 2023-12-31 | $544.89M Ended 2023-12-31 | $763.86M Ended 2024-06-30 |
| 3 years earlier | $234.69M Ended 2022-12-31 | n/a | $473.24M Ended 2022-12-31 | $688.09M Ended 2023-06-30 |
| 4 years earlier | $212.19M Ended 2021-12-31 | n/a | $439.69M Ended 2021-12-31 | $698.64M Ended 2022-06-30 |